San Diego-based mostly Viking Therapeutics marked alone as a serious competitor while in the weight loss drug marketplace in February just after revealing promising information from a mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied like a weekly injection and in March the